Abstract
Extrahepatic metastasis (EHM) of hepatocellular carcinoma (HCC) has recently been paradoxically increasing due to increased survival with effective locoregional therapies. The intrahepatic stage of the tumor is important for determining the risk of an extrahepatic lesion. Almost all patients with intrahepatic stage T3–4, with or without EHM, die of progressive intrahepatic HCC but not due to EHM; thus, the majority of patients with HCC and EHM need to undergo concurrent treatment for intrahepatic HCC. There is no convincing evidence, to date, that systemic chemotherapy improves overall survival. Sorafenib is the first systemic agent that has demonstrated a significant survival benefit in patients with advanced HCC; however, the modest improvement of 3 months is far from satisfactory. Therefore, most hepatologists still rely on the conventional multidisciplinary approach to treat patients with EHM. The concept of the multidisciplinary treatment is the combination of locoregional therapies for both the intrahepatic HCC and symptomatic EHM when confined to a single organ. Targeted therapy may be considered for patients with advanced intrahepatic HCC and multiple EHM, however the potential efficacy of this approach requires confirmation. The outcome of ongoing clinical trials of the multidisciplinary approach, combining conventional locoregional therapy and targeted systemic therapy, is pending.
References
1.
Kanda M, Tateishi R, Yoshida H, et al: Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. Liver Int 2008;28:1256–1263.
2.
Natsuizaka M, Omura T, Akaike T, et al: Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 2005;20:1781–1787.
3.
Katyal S, Oliver JH 3rd, Peterson MS, et al: Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000;216:698–703.
4.
Uka K, Aikata H, Takaki S, et al: Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007;13:414–420.
5.
Lin SC, Shih SC, Kao CR, et al: Transcatheter arterial embolization treatment in patients with hepatocellular carcinoma and risk of pulmonary metastasis. World J Gastroenterol 2003;9:1208–1211.
6.
Ishii H, Furuse J, Kinoshita T, et al: Extrahepatic spread from hepatocellular carcinoma: who are candidates for aggressive anti-cancer treatment? Jpn J Clin Oncol 2004;34:733–739.
7.
Burroughs A, Hochhauser D, Meyer T: Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 2004;5:409–418.
8.
Yeo W, Mok TS, Zee B, et al: A randomized phase III study of doxorubicin versus cisplatin/interferon α2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532–1538.
9.
Ganne-Carrié N, Trinchet JC: Systemic treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2004;16:275–281.
10.
Ferrari D, Di Maria G, Fazio N, et al: Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy. Anticancer Drugs 2008;19:837–840.
11.
Katamura Y, Aikata H, Kimura Y, et al: Successful treatment of pulmonary metastases associated with advanced hepatocellular carcinoma by systemic 5-fluorouracil combined with interferon-α in a hemodialysis patient. Hepatol Res 2009;39:415–420.
12.
Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.
13.
Llovet JM, Real MI, Montana X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734–1739.
14.
Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164–1171.
15.
Cammà C, Schepis F, Orlando A, et al: Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224:47–54.
16.
Llovet JM, Brú C, Bruix J: Prognosis of hepatocellular carcinoma the BCLC staging classification. Semin Liver Dis 1999;19:329–338.
17.
Witjes CD, Verhoef C, Verheul HM, et al: Systemic treatment in hepatocellular carcinoma: ‘a small step for man...’. Neth J Med 2009;67:86–90.
18.
Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34.
19.
Abou-Alfa GK: Selection of patients with hepatocellulacr carcinoma for sorafenib. J Natl Compr Canc Netw 2009;7:397–403.
20.
Yau T, Chan P, Ng KK, et al: Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009;115:428–436.
21.
Strebel BM, Dufour JF: Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 2008;8:1743–1749.
22.
Thomford NR, Woolner LB, Clagett OT: The surgical treatment of metastatic tumors in the lungs. J Thorac Cardiovasc Surg 1965;49:357–363.
23.
Lam CM, Lo CM, Yuen WK, et al: Prolonged survival in selected patients following surgical resection for pulmonary metastasis from hepatocellular carcinoma. Br J Surg 1998;85:1198–200.
24.
Gwak GY, Jung JO, Sung SW, et al: Long-term survival after pulmonary metastatectomy of hepatocellular carcinoma; treatment outcome or natural history? Hepatogastroenterology 2004;51:1428–1433.
25.
Park YJ, Lim do H, Paik SW, et al: Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J Gastroenterol 2006;41:1099–1106.
26.
Huo TI, Lin HC: Metastatic hepatocellular carcinoma: when, how, where and so what? Liver Int 2008;28:1183–1185.
27.
Seong J, Koom WS, Park HC: Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int 2005;25:261–265.
28.
Sakamoto Y, Kubota K, Mori M, et al: Surgical management for adrenal gland metastasis of hepatocellular carcinoma. Hepatogastroenterology 1999;46:1036–1041.
29.
Chang L, Chen YL, Kao MC: Intracranial metastasis of hepatocellular carcinoma: review of 45 cases. Surg Neurol 2004;62:172–177.
30.
Yen FS, Wu JC, Lai CR, et al: Clinical and radiological pictures of hepatocellular carcinoma with intracranial metastasis. J Gastroenterol Hepatol 1995;10:413–418.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
